Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.Read more
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
Find out more about potential partnering opportunities.
|NOV 20, 2017||Surrogate marker and design of Calliditas Therapeutics’ IgA nephropathy Phase 3 study agreed with the FDA|
|NOV 15, 2017||Pharmalink is renamed Calliditas Therapeutics|
|AUG 24, 2017||Thomas Eklund New Chairman of Pharmalink|